We only have this paper's title and publication details.
Read it at the sourcePhase II trial evaluated ponatinib’s efficacy for patients with metastatic gastrointestinal stromal tumor, suggesting a new potential therapy post-imatinib failure.
PFS by primary mutation
No takes yet. Share an insight, caveat, or question.
Falkenhorst et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: